Publication:
Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report

Simple item page
dc.contributor.authorÖZEN ALAHDAB, YEŞİM
dc.contributor.authorsAtug, Ozlen; Akin, Hakan; Alahdab, Yesim Ozen; Ceyhan, Berrin; Tozun, Nurdan; Ozdogan, Osman
dc.date.accessioned2022-03-14T04:30:54Z
dc.date.accessioned2026-01-10T17:12:00Z
dc.date.available2022-03-14T04:30:54Z
dc.date.issued2009
dc.description.abstractInterstitial pneumonitis is a rare but potentially fatal side effect occurring from 2 weeks to 16 weeks after the initiation of treatment with pegylated interferon alpha and ribavirin for chronic hepatitis C.Herein, we present a 68-year-old man with chronic hepatitis C virus infection who developed interstitial pneumonitis association with pegylated interferon after 36 weeks initiation of pegylated interferon-alpha and ribavirin therapy. He did not recover after discontinuation of pegylated interferon/ribavirin and improved by steroid therapy.
dc.identifier.doi10.1186/1757-1626-0002-0000006464
dc.identifier.issn1757-1626
dc.identifier.pubmedPMID: 20181162 PMCID: PMC2827138
dc.identifier.urihttps://hdl.handle.net/11424/238974
dc.language.isoeng
dc.relation.ispartofCases Journal
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleInterstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report
dc.typearticle
dspace.entity.typePublication
oaire.citation.startPage6464
oaire.citation.titleCases Journal

Files

Collections

Araştırma Çıktıları